[Effect of nizofenone on the symptomatic vasospasm after aneurysmal subarachnoid hemorrhage and its relationship to the levels of serum complements (CH50, C3 and C4)].
Serum complements (CH50, C3 and C4) after aneurysmal subarachnoid hemorrhage were measured in 42 patients over 2 to 3-week period. Nizofenone, an anti-vasospasmotic agent, was administered to 11 patients. In the nizofenone-treated group, 8 patients showed decreased serum C4 levels 5 days after the onset of subarachnoid hemorrhage, but among them, only 2 patients showed symptomatic vasospasm. Considering our previous data (majority of patients who showed decreased serum C4 levels presented with symptomatic vasospasm), these results suggest a favorable effect of nizofenone on the symptomatic vasospasm after aneurysmal subarachnoid hemorrhage.
Ogata
N
N
Department of Neurosurgery, National Cardiovascular Center, Suota City, Japan.
Yonekawa
Y
Y
Kawano
T
T
Tsukahara
T
T
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003167:Complement Activation; D003176:Complement C3 / Q000378:metabolism*; D003181:Complement C4 / Q000378:metabolism*; D015941:Complement Hemolytic Activity Assay; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D002532:Intracranial Aneurysm / Q000150:complications* / Q000276:immunology; D002546:Ischemic Attack, Transient / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D012422:Rupture, Spontaneous; D013345:Subarachnoid Hemorrhage / Q000150:complications* / Q000276:immunology
D003176:Complement C3; D003181:Complement C4; D007093:Imidazoles; C016910:nizofenone